Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database.

Rimple Jeet Kaur Jaykaran Charan Siddhartha Dutta Paras Sharma Pankaj Bhardwaj Praveen Sharma Halyna Lugova Ambigga Krishnapillai Salequl Islam Mainul Haque Sanjeev Misra

Published in: Infection and drug resistance (2020)

This study revealed that favipiravir appears to be a relatively safe drug. An undiscovered anti-inflammatory activity of favipiravir may explain the improvement in critically ill patients and reduce inflammatory markers. Currently, the data is based on very few patients. A more detailed assessment of the uncommon ADEs needs to be analyzed when more information will be available.

Keyphrases

adverse drug
electronic health record
end stage renal disease
sars cov
coronavirus disease
ejection fraction
newly diagnosed
chronic kidney disease
drug induced
emergency department
peritoneal dialysis
prognostic factors
big data
health information
social media
deep learning
patient reported